Alerts
Other content recommended for you
- Systematic evaluation of nine monogenic autoinflammatory diseases reveals common and disease-specific correlations with allergy-associated features
- Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
- Familial Mediterranean fever (FMF) and beyond: a new horizon. Fourth International Congress on the Systemic Autoinflammatory Diseases held in Bethesda, USA, 6–10 November 2005
- Autoinflammatory syndromes in neurology: when our first line of defence misbehaves
- Autoinflammatory diseases: update on classification diagnosis and management
- Classification criteria for autoinflammatory recurrent fevers
- Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry
- Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers
- Visual loss with chronic meningeal and systemic inflammation
- An International registry on Autoinflammatory diseases: the Eurofever experience